New drug BGB-23339 put to the test in healthy volunteers
NCT ID NCT05093270
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 34 times
Summary
This early-stage study tested the safety and how the body handles a new drug called BGB-23339 in 92 healthy adults. Participants received single or multiple doses of the drug, and researchers monitored for side effects and changes in vital signs and lab values. The goal was to gather initial safety information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOT DETERMINED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network
Melbourne, Victoria, VIC 3004, Australia
-
Q PHARM
Herston, Queensland, QLD 4006, Australia
-
The Affiliated Hospital of Qingdao University Branch West Coast
Qingdao, Shandong, 266555, China
Conditions
Explore the condition pages connected to this study.